Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768252 | 0.92 | TSHR (0.61) | TSHRTDP1L3MBTL1IDO1CHRM3 | |
| SCHEMBL4004770 | 0.89 | L3MBTL1 (0.58) | TSHRTDP1L3MBTL1IDO1CHRM3 | |
| SCHEMBL1066576 | 0.88 | TSHR (0.67) | TSHRTDP1L3MBTL1IDO1NAAA | |
| SCHEMBL13643219 | 0.87 | L3MBTL1 (0.65) | TSHRTDP1L3MBTL1IDO1LTA4H | |
| SCHEMBL2658064 | 0.86 | TSHR (0.54) | TSHRTDP1L3MBTL1IDO1CHRM3 | |
| Hydrochloric Acid SCHEMBL1409425 | 0.86 | TSHR (0.64) | TSHRTDP1L3MBTL1IDO1NAAA | |
| Water SCHEMBL28780406 | 0.86 | TSHR (0.64) | TSHRTDP1L3MBTL1IDO1NAAA | |
| SCHEMBL2657770 | 0.86 | TSHR (0.71) | TSHRTDP1IDO1CHRM3NAAA | |
| SCHEMBL3677409 | 0.85 | TSHR (0.54) | TSHRTDP1L3MBTL1IDO1NAAA | |
| SCHEMBL134086 | 0.83 | IDO1 (0.61) | TSHRIDO1CHRM3HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4100009-A1 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | Genzyme Corporation (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115427038-A | Methods of treating nervous system symptoms associated with lysosomal storage diseases | 建新公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2004037806-A1 | N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBONXAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040063170-A1 | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO & LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1344780-A1 | GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
| CN-1418219-A | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the prepararation of the derivatives | KISSEI PHARMACEUTICAL (JP) | 2003-05-14 | — | — | CN | disclosed |
| EP-1270584-A1 | GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0666262-B1 | Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same | CANON KK (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-5849217-A | Optically active compound, liquid crystal composition containing the same, liquid crystal device using the same, liquid crystal apparatus and display method | CANON KABUSHIKI KAISHA (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0666262-A1 | Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same | CANON KABUSHIKI KAISHA (JP) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | TSHR 3490/4885TDP1 4715/4885L3MBTL1 4015/4885 |
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | TSHR 835/4885TDP1 1253/4885L3MBTL1 275/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | TSHR 4196/4885TDP1 807/4885L3MBTL1 493/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | TSHR 2547/4885TDP1 1957/4885L3MBTL1 3424/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | TSHR 2412/4885TDP1 2339/4885L3MBTL1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.